New Zealand - English - Ministry for Primary Industries

virbac new zealand limited - cloxacillin sodium monohydrate; cloxacillin benzathine - cloxacillin sodium monohydrate 21.5 g/kg; cloxacillin benzathine 86 g/kg - antibiotic

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicl

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin sodium capsules are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). dicloxacillin sodium capsules may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. dicloxacillin sodium capsules are contraindicated in persons who have shown hypersensitivity to any of the penicillins or any component of the formulations.

Ireland - English - HPRA (Health Products Regulatory Authority)

ibigen srl - flucloxacillin sodium - powder for solution for injection/infusion - 250 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Ireland - English - HPRA (Health Products Regulatory Authority)

ibigen srl - flucloxacillin sodium - powder for solution for injection/infusion - 500 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Ireland - English - HPRA (Health Products Regulatory Authority)

ibigen srl - flucloxacillin sodium - powder for solution for injection/infusion - 1000 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Ireland - English - HPRA (Health Products Regulatory Authority)

ibigen srl - flucloxacillin sodium - powder for solution for injection/infusion - 2000 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

United States - English - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flucloxacillin sodium monohydrate, quantity: 545 mg (equivalent: flucloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: povidone; titanium dioxide; purified talc; brilliant blue fcf; iron oxide red; magnesium stearate; iron oxide yellow; gelatin; microcrystalline cellulose; sodium starch glycollate - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval granted as specified in the letter of 1 may 1992 from dr h. arora. indicated for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.